Sweetgreen, Inc. (SG) Gains Price Target Bump as Policy Optimism Lifts Restaurant Sector
On January 28, Goldman Sachs analyst Christine Cho raised the firm’s price target on Sweetgreen, Inc.
Insider Monkey Blog
Piper Sandler Sees Upside Potential in Kura Sushi USA, Inc. (KRUS) After Investor Meeting and Loyalty Platform Changes
On January 16, Piper Sandler analyst Brian Mullan raised the firm’s price target on Kura Sushi USA, Inc.
Benchmark Sees Continued Upside in The Chefs’ Warehouse, Inc. (CHEF) on Visible Operating Momentum
On January 29, Benchmark raised its price target on The Chefs’ Warehouse, Inc. (NASDAQ:CHEF) to $84 from $79 while keeping a Buy rating on the shares.
Morgan Stanley Still Bullish on Wingstop Inc. (WING)’s Growth Story After Target Cut
On January 20, Morgan Stanley lowered the firm’s price target on Wingstop Inc.
Cal-Maine Foods, Inc. (CALM)’s Long-Term Outlook Remains Intact Despite Short-Term Headwinds
On January 8, Stephens analyst Pooran Sharma lowered the firm’s price target on Cal-Maine Foods, Inc.
Freedom Capital Initiates Mama’s Creations, Inc. (MAMA) With Buy Rating, Citing National Expansion and Innovation
On January 14, Freedom Capital analyst Georgy Vashchenko initiated coverage of Mama’s Creations, Inc. (NASDAQ:MAMA) with a Buy rating and a $16 price target.
BMO Stays Bullish on Primo Brands Corporation (PRMB) Despite Near-Term Estimate Reset
BMO Capital analyst Andrew Strelzik lowered the firm’s price target on Primo Brands Corporation (NYSE:PRMB) to $35 from $39 but reiterated an Outperform rating on the shares...
Dutch Bros Inc. (BROS) Positioned for Continued Same-Store Sales Momentum, Says Citi
On January 26, Citi initiated coverage of Dutch Bros Inc. (NYSE:BROS) with a Buy rating and an $82 price target.
The ONE Group Hospitality, Inc. (STKS) Seen as Long-Term Opportunity Despite Q4 Revenue Miss
On January 16, Lake Street analyst Mark Smith lowered the firm’s price target on The ONE Group Hospitality, Inc.
JPMorgan Raises Celsius Holdings Inc (CELH) Price Target, Sees Earnings Upside From PepsiCo Partnership and Alani Nu Growth
JPMorgan raised its price target on Celsius Holdings, Inc (NASDAQ:CELH) to $77 from $68 on January 29 while maintaining an Overweight rating as part of its Q4 earnings preview...
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company...
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target.
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data
TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S.
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target.
Here is Why Hedge Funds Favor Advance Auto Parts (AAP)
On January 21, Aaron Reed from Northcoast Research indicated his optimism around Advance Auto Parts (NYSE:AAP).
Autoliv (ALV) Drives Some Near Term Optimism Despite Affordability Concerns
Junk’s upward revision was part of Baird’s broader adjustments across vehicle technology and mobility group, in line with the fourth quarter results preview.
Favorable Sector Outlook Bodes Well for Visteon (VC)
On January 15, Goldman Sachs analyst Mark Delaney reiterated his Buy rating on Visteon Corp (NASDAQ:VC), while lowering the price target from $130 to $120.
Latest Zero-Emission Offerings Spark Bullish Views on Garrett Motion (GTX)
As of the close of play on January 29, sentiment remains highly bullish around Garrett Motion (NASDAQ:GTX).
Goodyear (GT) Set to Benefit From Favorable Replacement Tire Market Potential
As of January 29 closing, Goodyear Tire & Rubber (NASDAQ:GT) carried moderately bullish consensus views.
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program
TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating.
Aptiv (APTV) Looking at More Realistic Value and Growth Propositions
On January 14, Joseph Spak from UBS reaffirmed his Neutral rating on Aptiv PLC (NYSE:APTV), while adjusting his estimated price target from $94 to $99.
2026 Labeled as a Transition Year for Mobileye (MBLY)
On January 23, George Gianarikas from Canaccord Genuity reaffirmed his Buy rating for Mobileye Global (NASDAQ:MBLY).
AutoZone (AZO) Showing Ambition Towards Accelerating Store Growth
On December 18, Christopher Horvers from JPMorgan maintained his Overweight rating on AutoZone Inc (NYSE:AZO), cutting down his price target estimate from $4,850 to $4,100 in ...
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target.
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)
TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 price target.
Alphabet Inc.’s Google Adds More Gemini AI Features to the Chrome Browser
On January 28, Alphabet Inc. (NASDAQ: GOOGL) announced that Google is adding additional Gemini AI features to the Chrome browser.
Here Is Why TSMC Could Be Investing More In the US?
On January 23, Reuters reported that the Taiwanese President expects increased semiconductor investment in Arizona.
Alibaba Group Holding’s Robovan Unit Set to Invest in Zelos Technology, WSJ Reports
According to reports, Alibaba Group Holding Limited’s (NYSE:BABA) robovan unit, Cainiao, is set to invest in Zelos Technology, a firm that offers cutting-edge L4 autonomous ...
Analysts Remain Bullish on Advanced Micro Devices Despite Rumours of MI450-Series Chips Behind Schedule
On January 26, UBS raised the price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) from $300 to $330.
Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262
Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher estimates from Johnson & Johnson’s new products.
Cathie Wood Remains Bullish on Broadcom Amid AI and Datacenter Exposure
On January 23, Cathie Wood made another purchase of Broadcom Inc. (NASDAQ: AVGO) shares, marking her fourth trade in the semiconductor firm this month.
B. Riley Liftes PT on Lam Research Corporation to $310, Reiterates Buy Rating
Craig Ellis from B. Riley raised the price target on Lam Research as the company exceeded Q2 FY2026 earnings and Q3 guidance.
Bernstein Raises PT on ASML Holding as the Company Updates 2026 Outlook
On January 29, TheFly reported that Bernstein analyst David Dai raised the price target on ASML Holding N.V. (NASDAQ:ASML) from $1,642 to $1,911.
Is Palantir Technologies One of the Hottest Stocks to Buy in 2026?
Palantir is scheduled to report its Q4 FY2025 results on Monday, February 2, 2026.
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target.
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results
TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating.
C3.ai (AI) Stays Central to AI Debate as Capital Intensity Challenges Investor Confidence
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Malta Gaming Authority Receives Surge in Online Gambling Licence Applications in 2025
In 2025, Malta Gaming Authority noted a significant increase in applications for online gambling licenses, illustrating continued interest from potential international licensees...
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)’s Carvykti Despite Sales Miss
TheFly reported on January 22 that H.C.
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)
TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, keeping an Overweight rating. The firm noted that Initial Phase 1 data for...
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal
TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating.
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress
TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating.
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007
TheFly reported on January 20 that Clear Street downgraded JANX to Hold from Buy and lowered the price target to $12 from $32.
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion
TheFly reported on January 13 that Leerink Partners lowered the price target on KURA to $20 from $25 and maintained an Outperform rating.
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play
TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a price target of $10, up from $8.
Here’s Why uniQure (QURE) Declined in Q4
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts
TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating.
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical takeover...
Hedge Fund Resource Center
